Sign In
Buy OVID
$2.44
-0.0100 (-0.408%)
At Close: Jul 17, 2026
武田宣佈2020會計年度第一季業績；確認管理層指引，並提高全年列報營業利潤和列報淨利潤
12:00am, Tuesday, 04'th Aug 2020
(美國商業資訊)--武田藥品工業株式會社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（簡稱「武田」）今天宣佈2020會計年度第一季（截至2020年6月30日�
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) („Takeda“) gab heute die Finanzergebnisse für das erste Quartal des Geschäftsjahres 2020 (
A Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) anunciou hoje os resultados financeiros do primeiro trimestre do ano fiscal d
Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020
12:00am, Saturday, 01'st Aug 2020
Takeda today presented three abstracts at the 72nd National Hemophilia Foundation’s Bleeding Disorders Conference.
Ovid Therapeutics: A Full Investment Analysis
02:07pm, Monday, 27'th Jul 2020
Today, we take an in-depth look at Ovid Therapeutics. The company has several trial readouts due out in the back half of this year.
3 Top Biotech Stocks to Buy Now
01:10pm, Saturday, 25'th Jul 2020
While large-cap biotech companies have been doing quite well, investors can frequently find market-beating performance in emerging biotechs developing cutting-edge treatments. First up is Ovid Therap
* Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing
Ovid Therapeutics (NASDAQ:OVID) Rating Reiterated by William Blair
01:32am, Sunday, 19'th Jul 2020
Ovid Therapeutics (NASDAQ:OVID)‘s stock had its “buy” rating reissued by stock analysts at William Blair in a note issued to investors on Friday, AnalystRatings.com reports. William Blair also i
Ovid Therapeutics (NASDAQ:OVID) PT Raised to $9.00
02:16pm, Thursday, 16'th Jul 2020
Ovid Therapeutics (NASDAQ:OVID) had its target price lifted by equities researchers at Citigroup from $8.00 to $9.00 in a note issued to investors on Tuesday, The Fly reports. The firm presently has a
Two Sigma Advisers LP Purchases 4,200 Shares of Ovid Therapeutics Inc (NASDAQ:OVID)
10:18pm, Wednesday, 15'th Jul 2020
Two Sigma Advisers LP raised its position in Ovid Therapeutics Inc (NASDAQ:OVID) by 21.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Ovid Therapeutics (NASDAQ:OVID) Shares Up 5.6% After Analyst Upgrade
01:52am, Wednesday, 15'th Jul 2020
Ovid Therapeutics Inc (NASDAQ:OVID)’s share price was up 5.6% during mid-day trading on Tuesday after Citigroup raised their price target on the stock from $8.00 to $9.00. Citigroup currently has a
Global Dry Eye Syndrome Treatment Market to Surpass US$ 31 Billion by 2027, Says Coherent Market Insights (CMI)
12:00am, Wednesday, 15'th Jul 2020
The global dry eye syndrome treatment market is expected to exhibit a CAGR of 8.1% during the forecast period (2020-2027).
Is Ovid Therapeutics Stock a Buy?
10:35am, Tuesday, 14'th Jul 2020
Shares of Ovid Therapeutics (NASDAQ: OVID) have more than doubled over the past four months, a performance the clinical-stage biotech company owes in part to a positive rating from an analyst. In Mar
Takeda Pharmaceutical Co Ltd (NYSE:TAK) Shares Acquired by Guggenheim Capital LLC
05:35am, Tuesday, 14'th Jul 2020
Guggenheim Capital LLC lifted its position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 15.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 15,609 sh
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countrie
